1-3 of 3 results for subject:Pfizer
Librarians' tools
- Search time
- 0.231 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Pfizer
- We searched for
- subject_t:Pfizer OR subject_ses:61578
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
My right hon. Friend will no doubt be aware of early-day motion 2786, which refers to the recent deal between Pfizer and Unichem. [That this House expresses deep concern over the decision by Pfizer to award the contract for sole supplying of its pharmaceutical products to one wholesaler Unichem; is...
My right hon. Friend will no doubt be aware of early-day motion 2786, which refers to the recent deal between Pfizer and Unichem. [That this House expresses deep concern over the decision by Pfizer to award the contract for sole supplying of its pharmaceutical products to one wholesaler Unichem; is...
Yes, I understand the concern that my hon. Friend raises. I hope he is able to get a slot for an Adjournment debate or a debate in Westminster Hall. I will pass on his concerns not only to our right hon. Friend the Secretary of State for Health, but to...
Yes, I understand the concern that my hon. Friend raises. I hope he is able to get a slot for an Adjournment debate or a debate in Westminster Hall. I will pass on his concerns not only to our right hon. Friend the Secretary of State for Health, but to...
That this House expresses deep concern over the decision by Pfizer to award the contract for sole supplying of its pharmaceutical products to one wholesaler Unichem; is alarmed that this has created a de facto monopoly for Unichem in that pharmacies have no choice about who they deal with if they want to purchase Pfizer products; is concerned that whereas choice and competition have kept prices down this action will lead to a worse deal for local pharmacists, the NHS and ultimately the general public; is deeply alarmed that if Unichem had a crisis in its distribution then other wholesalers would be unable to fill the gap left and thus people might not get the pharmaceutical products they absolutely rely on; and calls on the Office of Fair Trading and the Department of Health to investigate this issue with a focus on, respectively, the effect of this decision on unfair business practices and public health.
That this House expresses deep concern over the decision by Pfizer to award the contract for sole supplying of its pharmaceutical products to one wholesaler Unichem; is alarmed that this has created a de facto monopoly for Unichem in that pharmacies have no choice about who they deal with if...